Targeted Endogenous Bioelectric Modulation in Autism Spectrum Disorder: Real-World Clinical Outcomes of the REAC BWO Neurodevelopment–Autism Protocol

<b>Background:</b> Autism Spectrum Disorder (ASD) is characterized by atypical brain oscillatory dynamics and altered connectivity, impairing sensory integration, socio-communicative responsiveness, and behavioral regulation. <b>Methods</b>: Radio Electric Asymmetric Conveyer (REAC) technology delivers non-invasive neurobiological modulation through standardized, operator-independent protocols. The Brain Wave Optimization Neurodevelopment-Autism (BWO ND-A) protocol was designed to address oscillatory patterns frequently altered in ASD, aiming to promote network coherence and multidomain functional improvement. This retrospective pre-post single-arm study evaluated 39 children with ASD (31 males, 8 females; mean age 7.85 ± 2.90 years). All received one Neuro Postural Optimization (NPO) session to prime central nervous system adaptive capacity, followed by BWO ND-A (18 sessions, ~8 min each), administered 3-4 times daily over ~two weeks. The primary outcome was the Autism Treatment Evaluation Checklist (ATEC) total score; secondary outcomes were its four subscales. <b>Results:</b> Mean total ATEC decreased from 67.76 ± 16.11 to 56.25 ± 23.66 (mean change -11.51 ± 14.48; <i>p</i> < 0.0001; Cohen's dz = 0.78). Clinically meaningful improvement (≥8-point reduction) occurred in 59% of participants. In 10.3% of cases, caregiver ratings indicated an apparent worsening (≥8-point increase). However, no objective deterioration or adverse effects were observed. This pattern was most likely related to a transient phase of functional re-adaptation, during which emerging changes may initially be perceived by caregivers as worsening before stabilizing into improvement. <b>Conclusions:</b> While these findings suggest promising short-term real-world efficacy and safety, the absence of a control group, lack of objective neurophysiological measures, and no long-term follow-up limit causal inference. Future controlled studies with neurophysiological monitoring are needed to confirm the targeted neuromodulatory action and durability of effects.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-10-23
DOI
https://doi.org/10.3390/jcm14217500
Primary Topic
Neuroscience and Neural Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeted Endogenous Bioelectric Modulation in Autism Spectrum Disorder: Real-World Clinical Outcomes of the REAC BWO Neurodevelopment–Autism Protocol

Salvatore Rinaldi, Arianna Rinaldi, Vania Fontani, Hingrid Angélica Benetti Mota
Journal of Clinical Medicine
Neuroscience and Neural Engineering
article

Targeted Endogenous Bioelectric Modulation in Autism Spectrum Disorder: Real-World Clinical Outcomes of the REAC BWO Neurodevelopment–Autism Protocol

Salvatore Rinaldi, Arianna Rinaldi, Vania Fontani, Hingrid Angélica Benetti Mota
article en

Abstract

<b>Background:</b> Autism Spectrum Disorder (ASD) is characterized by atypical brain oscillatory dynamics and altered connectivity, impairing sensory integration, socio-communicative responsiveness, and behavioral regulation. <b>Methods</b>: Radio Electric Asymmetric Conveyer (REAC) technology delivers non-invasive neurobiological modulation through standardized, operator-independent protocols. The Brain Wave Optimization Neurodevelopment-Autism (BWO ND-A) protocol was designed to address oscillatory patterns frequently altered in ASD, aiming to promote network coherence and multidomain functional improvement. This retrospective pre-post single-arm study evaluated 39 children with ASD (31 males, 8 females; mean age 7.85 ± 2.90 years). All received one Neuro Postural Optimization (NPO) session to prime central nervous system adaptive capacity, followed by BWO ND-A (18 sessions, ~8 min each), administered 3-4 times daily over ~two weeks. The primary outcome was the Autism Treatment Evaluation Checklist (ATEC) total score; secondary outcomes were its four subscales. <b>Results:</b> Mean total ATEC decreased from 67.76 ± 16.11 to 56.25 ± 23.66 (mean change -11.51 ± 14.48; <i>p</i> < 0.0001; Cohen's dz = 0.78). Clinically meaningful improvement (≥8-point reduction) occurred in 59% of participants. In 10.3% of cases, caregiver ratings indicated an apparent worsening (≥8-point increase). However, no objective deterioration or adverse effects were observed. This pattern was most likely related to a transient phase of functional re-adaptation, during which emerging changes may initially be perceived by caregivers as worsening before stabilizing into improvement. <b>Conclusions:</b> While these findings suggest promising short-term real-world efficacy and safety, the absence of a control group, lack of objective neurophysiological measures, and no long-term follow-up limit causal inference. Future controlled studies with neurophysiological monitoring are needed to confirm the targeted neuromodulatory action and durability of effects.

Journal of Clinical MedicineVol. 14(21)
Deutsches Historisches Institut Rom (IT), Opto Eletrônica (Brazil) (BR)
Openalex Percentile: Top 67%
Neuroscience and Neural Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.